Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A novel dimercaptosuccinic acid-functionalized mesoporous alumina (DMSA-MA) is synthesized by the dicarboxylic acid groups of dimercaptosuccinic acid molecules coordinating to the Al
3+
ions located in the mesostructure. The as-prepared
DMSA
-MA composites possess a large surface area of 91.17 m
2
/g as well as a uniform pore size and a high pore volume of 17.22 nm and 0.23 cm
3
/g, respectively.
DMSA
coating of mesostructures significantly enhanced their selectivity for glycoprotein adsorption through a powerful hydrophilic binding force, and the maximum adsorption capacity of immunoglobulin G (IgG) can reach 2298.6 mg g
-1
. The captured IgG could be lightly stripped from the
DMSA
-MA composites with an elution rate of 98.3% by using 0.5 wt % CTAB solution as the elution reagent.
DMSA
-MA is further employed as a sorbent for the enrichment of IgG heavy chain and light chain from human serum sample. SDS-PAGE assay results showed the obtained IgG with high purity compared to that of the standard solution of IgG.
ACS
Appl Mater Interfaces 2019 Oct 02
PMID:DMSA-Functionalized Mesoporous Alumina with a High Capacity for Selective Isolation of Immunoglobulin G. 3149 Oct 81
